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TO THE EDITOR
We appreciate Italiano et al’s [1] interest in our article [2] and agree that our case definition, 
described in our methods as “intentionally specific,” may have excluded some travelers 
infected with Sarcocystis nesbitti. Nevertheless, we believe that published data from 
outbreak investigations in Malaysia offer ample evidence that peripheral eosinophilia and 
myositis are important distinguishing components of human acute muscular sarcocystosis 
(AMS) [2–8]. It is expected that some patients would not have these findings at any given 
point in their illness; indeed, our Figure 4 shows subthreshold laboratory values during the 
late phase of disease [2], a finding corroborated elsewhere [3–6]. We concur that some ill 
patients will not develop detectable eosinophilia or myositis at all. As in all infectious 
diseases, variations in the clinical manifestations, laboratory testing results, and the courses 
of illness should be expected. Such variation may stem from host factors, the infectious load, 
or the infecting Sarcocystis species [9] or even strain. In this light, performing serial clinical 
and laboratory investigations seems warranted when evaluating and managing patients with 
suspected AMS.
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Italiano et al express concern that we restricted “analysis to those persons who sought care 
after the fourth postdeparture week.” However, we excluded no data from patients 
presenting early. We did, however, confirm through a stratified subanalysis that the biphasic 
nature of AMS persisted after removing those patients who presented early, thereby 
strengthening the validity of that observation.
We believe that recommending routine use of expensive whole-body magnetic resonance 
imaging (MRI) to guide muscle biopsy in patients with suspected AMS [1, 3] must await 
evidence that MRI is superior to physical findings in locating areas of maximal 
inflammation in Sarcocystis species infections, that parasite encystation occurs 
preferentially in these same inflamed areas, and that biopsy itself is routinely indicated. We 
interpret the available MRI data as having confirmed edema at painful and visibly swollen 
sites but not necessarily as having found unsuspected occult edema [4, 5].We are unaware of 
published data attributing myositis to parasite encystation; the cause of myositis in AMS and 
its relationship to the local presence of tissue sarcocysts remains unknown. Although 
sarcocysts of some species predominate in cardiac, diaphragm, and tongue muscle [9, 10], 
there are no data demonstrating especially marked inflammation in these sites. The absence 
of inflammation immediately surrounding intramyocytic sarcocysts is well documented [2, 
3, 8–10]. Finally, with no proven treatment, invasive muscle biopsy may be better reserved 
for the sickest patients or for those requiring investigation of other treatable conditions 
rather than as a routine diagnostic pursuit to be done “wherever possible,” as recommended 
by Italiano et al [3].
We agree with Dr Italiano that the manifestations of human AMS require more study and 
therefore caution against hasty definitions, conclusions, and recommendations. Careful and 
thoughtful consideration of all new human and animal data on this disease as they emerge is 
warranted.
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